Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non Operating Income (2022 - 2025)

ARS Pharmaceuticals' Other Non Operating Income history spans 4 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 12.07% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $10.7 million, down 6.16%, while the annual FY2025 figure was $10.7 million, 6.16% down from the prior year.
  • Other Non Operating Income for Q4 2025 was $2.7 million at ARS Pharmaceuticals, up from $2.0 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $3.8 million in Q1 2023 and bottomed at -$151000.0 in Q1 2022.
  • The 4-year median for Other Non Operating Income is $2.8 million (2024), against an average of $2.3 million.
  • The largest annual shift saw Other Non Operating Income skyrocketed 6521.28% in 2023 before it dropped 22.71% in 2024.
  • A 4-year view of Other Non Operating Income shows it stood at $1.2 million in 2022, then soared by 164.99% to $3.1 million in 2023, then dropped by 1.08% to $3.0 million in 2024, then fell by 12.07% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Other Non Operating Income are $2.7 million (Q4 2025), $2.0 million (Q3 2025), and $2.7 million (Q2 2025).